Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Serous Adenocarcinoma 1

Interventions

Nivolumab 5pembrolizumab 4Temozolomide 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Rituximab 2Radiosurgery 2Paclitaxel 2Neoadjuvant Therapy 2Ipilimumab 2Gemcitabine 2Fluorodeoxyglucose F18 2Dexamethasone 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Biopsy 2Bevacizumab 2venetoclax 1theanine 1temsirolimus 1tafasitamab 1sugemalimab 1senicapoc 1semaglutide 1sacituzumab govitecan 1prednylidene 1pirtobrutinib 1perampanel 1paricalcitol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 30 days × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡